user
menu
letter
Sign InRegister
langEnglisharrow

Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRRC) Complex Protein (Monomer, MALS verified)

製品番号/仕様
価格
Availability
数量
HL3-H82E6-25ug
$125.00
In Stock - Delivery in 1-2 business days
HL3-H82E6-200ug
$700.00
In Stock - Delivery in 1-2 business days
HL3-H82E6
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
Request Quote
製品詳細
データ表示
Reviews & Citations
Resources
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

HLA-A*0201 & B2M & p53 (HMTEVVRRC)

Source

Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRRC) Complex Protein (HL3-H82E6) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & HMTEVVRRC peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & HMTEVVRRC).

Predicted N-terminus: Gly 25 & Ile 21

Molecular Characterization

Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRRC) Complex Protein is produced by co-expression of HLA-A*02:01 and B2M loaded with p53 peptide.

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-43 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 3 months under sterile conditions.
ACRO Quality Management System

バックグランド

TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (HMTEVVRRC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and HMTEVVRRC peptide of the p53.